Takeda Pharmaceutical Co., Ltd.

4,357.00 JPY
+64.00
+1.49%

Japan
Nov 16, 2018
Ticker
TKS(4502)
Prev. close
4,293
Market cap (JPY)
3,411.65B
Market cap (USD)
30,087.79M
Shares
794.70M

In the news

Takeda to float 7.5bn euros in bonds to fund Shire purchase Nov 17, 2018
Japanese flu vaccine maker taps tobacco plants for fast output Nov 7, 2018
Takeda secures $4.5bn in long-term loans for Shire deal Oct 27, 2018
Takeda shareholders demand veto over Shire-size purchases May 31, 2018
Band of Takeda shareholders opposes Shire takeover May 28, 2018

See more articles on Takeda Pharmaceutical Co., Ltd.

Business Summary

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Financial Highlights

Mar 2018	JPY	USD
Revenue	1,770.53B	15,974.84M
Gross Profit	1,148.86B	10,365.80M
Operating income	195,320M	1,762.30M
Income before tax	217,205M	1,959.76M
Net income	186,886M	1,686.20M
EBITDA	377,447M	3,405.56M
Diluted EPS	237.55	2.14
Dividends Per Share	180	1.62
Total Assets	4,106.46B	38,612.71M
Total liabilities	2,089.05B	19,643.19M
Total equity	1,997.42B	18,781.60M
Operating cash flow	379,600M	3,424.99M
	Currency in JPY	Currency in USD

Historical Data

JPY | USD

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018
Revenue	1,691.68B	1,777.82B	1,807.37B	1,732.05B	1,770.53B
Gross Profit	1,060.98B	1,134.39B	1,161.84B	1,017.65B	1,148.86B
Operating income	145,604M	195,804M	175,770M	86,972M	195,320M
Income before tax	158,851M	-145,437M	120,542M	143,346M	217,205M
Net income	106,658M	-145,775M	80,166M	114,940M	186,886M
EBITDA	332,856M	387,391M	353,275M	258,398M	377,447M
Diluted EPS	134.95	-185.37	101.71	146.25	237.55
Dividends Per Share	180	180	180	180	180
Total Assets	4,569.14B	4,296.19B	3,824.08B	4,346.79B	4,106.46B
Total liabilities	2,028.50B	2,090.01B	1,812.88B	2,397.82B	2,089.05B
Total equity	2,470.73B	2,137.04B	1,948.69B	1,894.26B	1,997.42B
Operating cash flow	148,335M	183,441M	26,552M	260,067M	379,600M

	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018
Revenue	16,887.88M	16,183.14M	15,050.91M	15,994.93M	15,974.84M
Gross Profit	10,591.64M	10,326.11M	9,675.22M	9,397.74M	10,365.80M
Operating income	1,453.54M	1,782.36M	1,463.72M	803.15M	1,762.30M
Income before tax	1,585.79M	-1,323.88M	1,003.81M	1,323.75M	1,959.76M
Net income	1,064.75M	-1,326.95M	667.58M	1,061.43M	1,686.20M
EBITDA	3,322.86M	3,526.33M	2,941.89M	2,386.22M	3,405.56M
Diluted EPS	1.34	-1.68	0.84	1.35	2.14
Dividends Per Share	1.79	1.63	1.49	1.66	1.62
Total Assets	44,367.08M	35,823.98M	34,023.62M	39,009.18M	38,612.71M
Total liabilities	19,697.13M	17,427.69M	16,129.56M	21,518.70M	19,643.19M
Total equity	23,991.25M	17,819.86M	17,337.88M	16,999.56M	18,781.60M
Operating cash flow	1,480.81M	1,669.82M	221.11M	2,401.63M	3,424.99M

Valuation Measures

Mar 2018
PER	21.65
ROA	4.42%
ROE	9.60%
Operating margin	11.03%
Profit margin	10.55%

Key executives

President, CEO & Representative Director: Christophe Weber
Chief Financial Officer: Costa Saroukos
Director, Chief Medical & Scientific Officer: Andrew S. Plump
Executive Officer & Global General Counsel: Yoshihiro Nakagawa
Global Human Resources Officer & Executive Officer: David Osborne

Shareholders

Nippon Life Insurance Co. (5.4%)
The Vanguard Group, Inc. (3.8%)
Nomura Asset Management Co., Ltd. (3.2%)
Causeway Capital Management LLC (2.5%)
Mondrian Investment Partners Ltd. (2.3%)
Takeda Science Foundation (2.2%)
Wellington Management Co. LLP (1.9%)
Glenview Capital Management LLC (1.8%)
BlackRock Fund Advisors (1.7%)
State Street Global Advisors Ltd. (1.6%)

Contact Details

Website:http://www.takeda.co.jp
Address: 4-1-1 Dosho-machi, Chuo-Ku, Osaka, 540-8645, Japan
Phone: +81.6.6204.2111

Related Companies

Takeda Consumer Healthcare Co. Ltd.
Takeda Pharmaceutical Director Incentive Plan
Takeda Pharmaceutical Employee Incentive Plan
Oy Leiras Takeda Pharmaceuticals AB
Takeda Architectural Design Consulting (Shanghai) Co. Ltd.
Takeda Pharma AB
Takeda Development Center Americas, Inc.
Takeda Ukraine LLC
Takeda Pharmaceuticals Taiwan Ltd.
Takeda SRL
Takeda Hellas SA
Takeda Christiaens SCA/CVA
Takeda Belgium SCA/CVA
Takeda Vaccines Pte Ltd.
Takeda Pharmaceuticals (Asia Pacific) Pte Ltd.
Takeda Development Center Asia Pte Ltd.
Takeda Pharma Sp zoo
Takeda Mexico SA de CV
Takeda Kazakhstan LLP
Takeda Pharmaceuticals Korea Co., Ltd.
Takeda Farmaceutica Espana SA
Takeda Pharma Ltda.
Takeda Distribuidora Ltda.
Takeda Vaccines, Inc.
Takeda Pharma SA
Takeda Pharma Vertrieb GmbH & Co. KG
Takeda (China) Holdings Co. Ltd.
Takeda Pharmaceutical (China) Co. Ltd.
Takeda Pharmaceuticals LLC
Takeda Nederland BV

Competitors

Dr. Reddy's Laboratories Ltd.
Ipsen SA
Amgen Inc.
RedHill Biopharma Ltd.
Hypera S.A.
YungShin Global Holding Corp.
MorphoSys AG
Celgene Corporation
Assembly Biosciences, Inc.
Peptron. Inc.
Galapagos NV
Shire PLC
CymaBay Therapeutics, Inc.
Protagonist Therapeutics, Inc.
Ironwood Pharmaceuticals, Inc. Class A
Seattle Genetics, Inc.
Albireo Pharma, Inc.
Sierra Oncology, Inc.
Nektar Therapeutics
Miragen Therapeutics, Inc.
Adaptimmune Therapeutics PLC Sponsored ADR
arGEN-X SE
Karyopharm Therapeutics, Inc.
BeiGene, Ltd.
Synergy Pharmaceuticals, Inc.
Golden Biotechnology Corp.
Atara Biotherapeutics Inc
Blueprint Medicines Corp.
Deciphera Pharmaceuticals, Inc.
SillaJen, Inc.

Last Updated on 16 Nov, 2018

Welcome to our new website

Takeda Pharmaceutical Co., Ltd.

Japan

Ticker

Prev. close

Market cap (JPY)

Market cap (USD)

Shares